Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
Keywords:
psoriasis, tildrakizumab, biologic drug, anti-IL-23 monoclonal antibodyAbstract
Introduction: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis.
Objectives: This study aimed to evaluate the effectiveness, safety and survival of tildrakizumab in the medium term (48 weeks) in psoriatic patients failure to previous biologic treatment in a real world setting.
Methods: This was a retrospective, multicenter observational study that included adult patients with moderate-to-severe plaque psoriasis, failure to previous biologic therapy, consecutively treated with tildrakizumab. PASI and BSA values were recorded at baseline, at 12 and 48 weeks of treatment. Safety and tolerability of tildrakizumab were investigated by examining the presence of any adverse events.
Results: Overall 51 patients were enrolled. Baseline disease severity was moderate to severe with a mean PASI score of 19.2 ± 8.5, mean BSA of 16 ± 10.4, and mean DLQI of 18.2 ± 6.8. A significant reduction in the mean PASI score was detected at 12 weeks of tildrakizumab therapy (3.5 ± 2.7, p < 0.001), with a further improvement at week 48 (0.6 ± 1.5, p < 0.001). At week 12, there was a great improvement in BSA score for all groups (p <0.001) with further increase at week 48. The effectiveness was confirmed also by DLQI assessment, with a significant decrease at week 12 and even more at week 48 (p <0.001).
Conclusions: This study confirms the effectiveness of tildrakizumab in daily clinical practice in patients with moderate-to-severe plaque psoriasis.
References
Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021 Feb 20;397(10275):754-766. doi: 10.1016/S0140-6736(21)00184-7.
Markham A. Tildrakizumab: First Global Approval. Drugs. 2018;78(8):845–9. doi: 10.1007/s40265-018-0917-3.
Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br. J. Dermatol. 2015, 173, 930–939. doi: 10.1111/bjd.13932.
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (ReSURFACE 1 and ReSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet. 2017, 390, 276–288. doi: 10.1016/S0140-6736(17)31279-5.
Burlando M, Castelli R, Cozzani E, Parodi, A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021-2-6. doi: 10.7573/dic.2021-2-6.
Galán-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R. Tildrakizumab: Short-term efficacy and safety in real clinical practice. Int J Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840.
Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-il-23p19 biologic tildrakizumab: Results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615-619. doi: 10.1159/000519924.
Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. Dermatol Ther. 2022, 35(6):e15488. https://doi.org/10.1111/dth.15488 (Epub 2022 Apr 11. PMID:35384168;PMCID: PMC9287013).
Simpson K, Low ZM, Howard A, Kern JS. Successful management of treatment resistant nail psoriasis with tildrakizumab. Australas. J. Dermatol. 2021;62:390–393. doi: 10.1111/ajd.13642.
Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022;11(9):2631. doi: 10.3390/jcm11092631.
Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547-1548. doi: 10.1111/bjd.17580.
Torres T, Puig L, Vender R, et al. Drug Survival of Interleukin (IL) 17 and IL 23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi country, Multicentric Cohort Study. Am J Clin Dermatol. 2022;23(6):891-904. doi: 10.1007/s40257-022-00722-y.
Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55–9. https://doi.org/10.1177/24755303221077211.
Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93-103. doi: 10.1111/jdv.18594.
Poulin Y, Ramon M, Rosoph L, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1500–9. https://doi.org/10.1111/jdv.16187 (PMID:31919889).
Graier1 T, Weger W, Jonak C, et al. Real world effectiveness of anti interleukin 23 antibodies in chronic plaque type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078. doi: 10.1038/s41598-022-18790-9.
Published
Issue
Section
License
Copyright (c) 2023 Eugenia Veronica Di Brizzi, Dario Buononato, Pierfrancesco Benvenuto, Giuseppe Argenziano, Rocco De Pasquale, Carmen Silvia Fiorella, Claudia Gioffrè, Maria Letizia Musumeci, Giovanni Palazzo, Leonardo Zichichi, Anna Balato
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
